IP Library Granted Patent US 12,005,083
Granted Patent B1
US 12,005,083 · App. 16/910,849 · Granted Jun 11, 2024

Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof

Inventors: Michael Bernard Miklus (Essex Junction, VT); Anja Monika Wittke (Munich, DE); Pedro Antonio Prieto (Columbus, OH); Cynthia M. Barber (Gordonsville, VA)
Assignee: PBM Nutritionals, LLC
A61K35/20A23L2/66A23L33/12A23L33/125A23L33/15A23L33/19A23L33/40A61K9/0056A61K9/0095A61K31/202A61K31/355A61K31/375A61K31/661A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,083
App. No.
16/910,849
Granted
Jun 11, 2024
Kind
B1
Abstract

A nutritional composition that includes a milk fat globule membrane component, at least one human milk oligosaccharide, and at least one additional component chosen from the group consisting of DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin. The nutritional composition is in the form of a ready-to-drink composition, a food supplement, an extruded food bar, or a solid oral dosage form. The nutritional composition is typically administered or provided to adults, children, or infants through consumption.

Claims (11)

1. A method for supporting cognitive function and/or neuron cellular health in an individual in need thereof, comprising the step of administering to the individual a therapeutically effective amount of a nutritional composition,

wherein the nutritional composition comprises a milk fat globule membrane component, at least one human milk oligosaccharide, and docosahexaenoic acid (DHA),

wherein the DHA is converted to a phospholipid form of the DHA in the gastrointestinal tract of the individual, and

wherein the level of the phospholipid form of the DHA in the blood of the individual is increased following said administering as compared to blood of an individual administered an otherwise identical nutritional composition not comprising said at least one human milk oligosaccharide.

2. The method of claim 1 , wherein the at least one human milk oligosaccharide comprises 2′-fucosyllactose (2′FL) and the nutritional composition further comprises at least one additional component chosen from the group consisting of arachidonic acid (ARA), Vitamin E, Vitamin C, and sphingomyelin.

3. The method of claim 1 , wherein the milk fat globule membrane has a lactose content of not more than about 5% by weight of the milk fat globule membrane component.

4. The method of claim 3 , wherein the milk fat globule membrane component has a protein content of at least about 75% by weight of the milk fat globule membrane component.

5. The method of claim 1 , wherein the at least one human milk oligosaccharide consists of 2′FL and is free of any dietary butyrate.

6. The method of claim 1 , wherein the at least one human milk oligosaccharide comprises at least one human milk oligosaccharide chosen from the group consisting of fucosyllactose, 2′FL, 3FL, Lacto-N-fucopentaose I (LNFP I), LNFP II, LNFP III, LNFP V, and mixtures thereof.

7. The method of claim 6 , wherein the at least one human milk oligosaccharide is 2′FL and the milk fat globule membrane component comprises from about 10% to about 25% fat by weight of the milk fat globule component; water present in an amount such that the milk fat globule component has a moisture content of not more than 7% by weight of the milk fat globule component; ash present in an amount of not more than 5% by weight of the milk fat globule component; and one or more phospholipids where the total amount of phospholipids in the milk fat globule component is from about 4% to about 9% by weight of the milk fat globule component.

8. The method of claim 1 , wherein the nutritional composition is free of butyrate.

Assignments (2)
SECURITY AGREEMENT Recorded Jun 13, 2022
From: L. PERRIGO COMPANY; PBM NUTRITIONALS, LLC; PERRIGO DIABETES CARE, LLC; RANIR, LLC; OMEGA PHARMA INNOVATION & DEVELOPMENT NV; PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY COMPANY
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 060362/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2022
From: MIKLUS, MICHAEL BERNARD; WITTKE, ANJA MONIKA; PRIETO, PEDRO ANTONIO; BARBER, CYNTHIA M.
To: PBM NUTRITIONALS, LLC
Reel/Frame 059406/0352 →